Aurobindo Pharma has increased its Rs. 800 crore share buyback schedule, record date announced

Aurobindo Pharma through tender offer route Rs. 800 crore, the offer will open on April 23 and close on April 29, according to its offer letter. Company Rs. 1,475 per share will buyback 54.23 lakh shares, representing about 0.93% of its total outstanding shares.

The record date for determining eligible shareholders has been fixed on April 17, with the letter of offer sent to shareholders on April 21. The buyback schedule implies a tight execution window. The offer opens on April 23 and closes on April 29, with settlement expected to be completed by May 7.

Under the buyback entitlement structure, relatively high acceptance ratio is allotted to the small shareholders. Reserved category investors are entitled to 7 shares for every 61 shares held, while general category investors are entitled to 2 shares for every 249 shares.

The structure aims to provide better participation for retail investors, though final acceptance will depend on overall subscription levels.

The size of the buyback, at 0.93% of total outstanding equity, indicates a modest reduction in share capital. While not materially altering the equity base, the move signals capital allocation intent and potential additional cash deployment.

Rs. 800 crore expenditure represents a small portion of the company’s balance sheet, indicating that the buyback is more strategic than transformational in nature.

Buybacks at a premium to prevailing market prices are often interpreted as a sign of management’s confidence in intrinsic value, while also giving shareholders an opportunity to exit at a fixed price.

The company has opted for the tender offer route, where eligible shareholders can tender shares within a specified window and receive proceeds based on the acceptance ratio. Unlike an open market buyback, a tender offer provides price certainty but involves pro rata acceptance, meaning that not all tendered shares can be bought back.

Investors will look closely at the buyback price relative to the prevailing market price to assess arbitrage opportunities. Participation levels, especially from institutional investors, will determine the final acceptance ratio.

(Disclaimer: Recommendations, suggestions, opinions and views given by experts are their own. These do not represent the views of Economic Times)